Narmafotinib

Cat. No.: HY-145652

CAS No.: 1393653-34-3

Molecular Formula: $C_{28}H_{32}F_3N_5O_2$

Molecular Weight: 527.58

Target: FAK

Pathway: Protein Tyrosine Kinase/RTK

Storage: 4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (189.54 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8954 mL	9.4772 mL	18.9545 mL
	5 mM	0.3791 mL	1.8954 mL	3.7909 mL
	10 mM	0.1895 mL	0.9477 mL	1.8954 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Narmafotinib (AMP-945) is an inhibitor of the enzyme focal adhesion kinase (FAK, K_D=0.21 nM). Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC_{50}=7 nM and exhibits low general cellular toxicity (IC_{50}=2.7 μM, MDA-MB-231 cells)[1][2].

REFERENCES

[1]. Street I, et al. Abstract LB-308: combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer[J]. Cancer Research, 2012, 72(8_Supplement): LB-308-LB-308.

[2]. Amplia Therapeutics completes single-dose study of AMP945

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA